Physician profile
Jeff C Rickert
NPI 1972719151
$8,653.80
in general payments reported to CMS, 2019-2025
52 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,100 · 2022: $2,417 · 2023: $1,149 · 2024: $1,424 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,137.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,311.62 | 2022 | |
| Abbott Laboratories | $976.43 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $881.08 | 2021-2025 | |
| Amgen INC. | $591.07 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $581.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $517.69 | 2021-2024 | Nexletol |
| Pfizer INC. | $352.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $330.35 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Corium, LLC | $327.82 | 2024-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $284.22 | 2021-2024 | |
| Lilly USA, LLC | $209.53 | 2021-2025 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $206.37 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $195.49 | 2021-2025 | Veozah |
| Stryker Corporation | $166.01 | 2024 | Mako |
| Mylan Specialty L.P. | $128.92 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeff Rickert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.